Success for Andexanet alfa in trial reversing anticoagulation effect of Eliquis - Portala Pharma
Portola Pharmaceuticals has announced that its first Phase III study of andexanet alfa, a potential universal Factor Xa inhibitor antidote and FDA - designated breakthrough therapy, met its primary and secondary endpoints with high statistical significance. Andexanet alfa was well tolerated with no serious adverse events reported.
Top-line efficacy data from the first of two ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies demonstrated that an intravenous (IV) bolus of andexanet alfa immediately and significantly reversed the anticoagulation activity of Bristol-Myers Squibb Company and Pfizer Inc.'s direct Factor Xa inhibitor Eliquis (apixaban).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins